New heart mapping technique aims to stop Life-Threatening rhythms

NCT ID NCT06937983

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new method called decrement evoked potential (DeEP) mapping to guide catheter ablation for ventricular tachycardia (VT) in people with structural heart disease. VT is a fast, dangerous heart rhythm that can cause sudden cardiac arrest. The standard ablation procedure uses heat to destroy diseased heart tissue, but finding the exact trouble spots is often difficult. Researchers will enroll 77 adults with implantable defibrillators and use the DeEP mapping to target ablation more precisely. Patients will be followed for 12 months to see if this approach reduces VT episodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
catheter ablation procedure guided by decrement evoked potential mapping
What this could lead to
If successful, this could make VT ablation more effective at preventing dangerous heart rhythm episodes, reducing the need for shocks from implantable defibrillators.
What could go wrong
This is a small, early-stage study (77 participants) testing a refined technique. The new mapping method may not improve outcomes over standard approaches, and ablation carries risks like bleeding, infection, or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STRUCTURAL HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University Hospitals Coventry & Warwickshire NHS Trust

    RECRUITING

    Coventry, West Midlands, CV2 2DX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.